MARKET

TLSA

TLSA

TIZIANA LIFE SCIENCES PLC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.020
+0.040
+1.34%
Opening 13:58 02/26 EST
OPEN
2.970
PREV CLOSE
2.980
HIGH
3.060
LOW
2.820
VOLUME
126.79K
TURNOVER
--
52 WEEK HIGH
12.17
52 WEEK LOW
0.6200
MARKET CAP
293.86M
P/E (TTM)
-4.5523
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report
NEW YORK and LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that an interview with i...
GlobeNewswire · 12h ago
ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director
SINGAPORE, Feb. 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Neil Gra...
GlobeNewswire · 02/18 12:00
Tiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference
NEW YORK and LONDON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today ...
GlobeNewswire · 02/16 15:02
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director
NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today ...
GlobeNewswire · 02/05 07:00
Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody
Zacks.com · 02/03 15:11
Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody
Zacks · 02/03 15:11
Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview
NEW YORK and LONDON, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA/LSE:TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today anno...
GlobeNewswire · 02/03 07:00
Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview
NEW YORK and LONDON, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA/LSE:TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today anno...
GlobeNewswire · 02/03 07:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TLSA. Analyze the recent business situations of TIZIANA LIFE SCIENCES PLC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TLSA stock price target is 9.50 with a high estimate of 11.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 35
Institutional Holdings: 6.41M
% Owned: 6.59%
Shares Outstanding: 97.31M
TypeInstitutionsShares
Increased
10
279.05K
New
14
1.14M
Decreased
5
54.75K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.22%
Pharmaceuticals & Medical Research
-0.65%
Key Executives
Chairman/Director
Gabriele Cerrone
Chief Executive Officer/Chief Scientific Officer/Director
Shailubhai Kunwar
Chief Financial Officer
Tiziano Lazzaretti
Chief Operating Officer
James Tripp
Executive Director
Thomas Adams
Other
Neil Graham
Secretary
P. Cooper
Non-Executive Director
John Brancaccio
Non-Executive Director
Percy Lomax
Non-Executive Director
Willy Simon
Non-Executive Director
Leopoldo Zambeletti
  • Dividends
  • Splits
  • Insider Activity
No Data
About TLSA
Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its lead product candidates include Milciclib (TZLS-201) and Foralumab (TZLS-401). Its products also include Anti IK-6r (TZLS-501) and StemPrintER. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib has completed Phase IIa trials as a monotherapy for the treatment for thymic carcinoma and hepatocellular carcinoma (HCC). The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. Foralumab has completed Phase II trial and has potential application in a wide range of autoimmune and inflammatory diseases.

Webull offers kinds of Tiziana Life Sciences PLC - ADR stock information, including NASDAQ:TLSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TLSA stock methods without spending real money on the virtual paper trading platform.